ORYX' Oncolytic Virus ParvOryx Successfully Completes Phase I/IIa Trial to Treat Glioblastoma Multiforme
16-Jun-2015
- Germany
Unlike other natural or modified oncolytic viruses currently under investigation, H-1PV does not affect normal cells and is not pathogenic to humans. H-1PV acts at relatively low multiplicities of infection. The virus exerts a cytotoxic/oncolytic effect, predominantly mediated by the non-structural protein (NS1). In addition, viral oncolysis induces a strong and lasting tumor-specific immune response (bystander effect).
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.